Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Vanderbilt-Ingram Cancer Center, Nashville, TN, United States

Survival: 15.9 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Nashville, TN
Hospital: Vanderbilt-Ingram Cancer Center
Journal: Link
Date: 2/2012

This phase 2 study involved 132 previously treated advanced metastatic melanoma patients who have a BRAF V600-mutation in the cancer cells. The median patient age was 51.5 years and 61% were male.

Patients were treated with the biologic therapy agent vemurafenib, which is a kinase inhibitor specific to a mutation in the protein called BRAF V600E.

There was one reported treatment-related death due to kidney failure. Joint pain, rash, fatigue, and alopecia were also reported.

The median overall survival was 15.9 months.

This study was supported by the pharmaceutical company Hoffmann-LaRoche.

Correspondence: Dr. Jeffrey A. Sosman; email:

E-mail to a Friend Email Physician More Information